the Bl drug candidate is one of several existing immuno-oncology programs that have been enabled through theCompany's proprietary OGAP
target discovery platform.
Christian Rohlff, chairman and chief executive officer of Oxford BioTherapeutics, said, "Boehringer Ingelheim is one of the world's leading oncology companies and their decision to exercise an option on a second target is a further significant endorsement of our unique OGAP
holds the world's largest proprietary collection of proteins represented by the database, which contains over 1 million peptide sequences from 50 tissues and 60 disease states, mapped to approximately 15,000 genes and over 8 million single nucleotide polymorphism and haplotypes.
Overall, unadjusted outcomes distributions for OGAP
categories roughly matched distributions adjusting for model covariates, generally repeating the pattern of findings reported in Table 5.
Oxford BioTherapeutics' pipeline of ADCs is based on novel targets, discovered with its OGAP
technology, combined with proprietary antibody and cancer toxin technologies brought together through a series of collaborations with leading companies in the field.
The company's pipeline of ADCs is based on novel targets, identified with its OGAP
technology, combined with proprietary antibody and cancer toxin technologies brought together under a number of partnerships with major players in the field.
The analytic model had a hierarchical structure with assessment waves nested within subject, and subjects nested within the four OGAP
groups created based on assistance pattern and other legal income.
The target was discovered using Oxford BioTherapeutics' proprietary OGAP
system, which incorporates one of the world's largest proprietary proteomic databases, integrating clinical, experimental and expression data.
29 April 2013 - UK biotechn group Oxford BioTherapeutics (OBT) and German drug maker Boehringer Ingelheim have struck a deal to discover novel cancer antibody targets using OBT's OGAP
discovery platform, the parties said today.
The target was discovered using Oxford BioTherapeutics proprietary OGAP
system, which incorporates one of the worlds largest proprietary proteomic databases, integrating clinical, experimental and expression data.
USAID plans to further expand capacity of the dam by installing a third turbine (which there is a berth for but which never had a turbine installed.) In an operation involving 4,000 NATO troops (Operation Ogap
Tsuka), components of the third turbine were successfully delivered to the dam in September 2008.
OBT plans to use the CHEF1 system for the production of its oncologic therapeutic antibodies, each of which is directed to a novel target identified by OBT using its OGAP